• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deal search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
      • Deals search
      • Exits search
      • Funds search
      • Sponsors search
      • Advisers search
      • LPs search
      • League tables
      • Reports
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
UNQUOTE
  • Exits

Eurazeo-backed DORC catches the eye of dealmakers with H2 process anticipated

  • Claude Risner and Rachel Lewis
  • 05 June 2023
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

DORC is once again turning heads in the M&A with the Dutch med-tech company’s owner, Eurazeo, to launch a sale, three sources familiar with the situation said.

Dealmakers have set their hopes on a H2 2023 launch for the company despite healthcare M&A struggling to get into gear so far in 2023.

With a sellside advisor still be appointed, the sources predicted that Eurazeo will wait until Q3 2023 before launching a process for this prized asset.

Numerous healthcare M&A transactions have fallen by the wayside this year, despite the sector outperforming. Large cap deals such as European Dental Group and VetPartners have been particularly tough to get over the line. But DORC is a strong sale candidate as it's well into the fourth year of the sponsor's holding period and, according to the second and third source, is performing well.

DORC has a Likely-to-Exit score of 36 out of 100 according to Mergermarekt's Likely-to-Exit model which tracks the likelihood of sponsors to exit a portfolio asset. The top input for its score under the model is the days held by the sponsor.

The company generated around EUR 45m EBITDA in 2021, meeting its forecast from 2017, the third source said. This was achieved despite the coronavirus pandemic interfering with routine hospital surgery, hitting equipment suppliers.

DORC could also further expand into China, which could might tempt Chinese private equity firms into an auction, the first source said. The rate of growth in vitrectomy machines in China is among the highest in the world as the population ages and conditions such as diabetes become more prevalent.

DORC's sale in early 2019 was hotly contested with sponsors CVC and Nordic as well as strategics such as Johnson & Johnson competing to acquire the manufacturer of ophthalmic surgery instruments from Montagu. Danaher, Carl Zeiss, Alcon and Bausch were also tipped as possible strategic buyers last time around.

In the end, Eurazeo won out with a EUR 430m EV bid. In 2020, it made a EUR 80m follow-on investment from its Eurazeo China Acceleration Fund.

Last year, DORC refinanced its senior debt through a cov-lite uni-tranche provided by Goldman Sachs, Partners Group, Bridgepoint, BOI and SMBC, according to a report by Mergermarket sister publication Debtwire.

Eurazeo took out a dividend through the deal, which was levered at around 6x EUR 45m structuring EBITDA.

Otherwise known as Dutch Ophthalmic Research Center, DORC is a manufacturer of EVA as well as medical consumables. It has a razor-blade model whereby it sells high-end surgical equipment as well as gauges, tamponades and other consumables.

Eurazeo did not return a request for comment.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Exits
  • Benelux
  • Healthcare
  • Mergermarket
  • Eurazeo
  • Netherlands

More on Exits

Partners Group to release IMs for Civica sale in mid-September
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • Exits
  • 04 September 2023
Actera Group explores strategic options for Celebi Ground Handling
Actera Group explores strategic options for Celebi Ground Handling

Several investors placed bids for the company in 2022 but mismatch in pricing didn't lead to a deal

  • Exits
  • 30 August 2023
Norstat owner Triton Partners explores sale via William Blair
Norstat owner Triton Partners explores sale via William Blair

GP has owned the Norway-headquarterd market research business for almost four years

  • Exits
  • 25 August 2023
IK Investment-backed Eres expected to hit the auction block by 2024
IK Investment-backed Eres expected to hit the auction block by 2024

French employee savings distribution and management firm could be valued at a few hundred million euros

  • Exits
  • 24 August 2023

Latest News

Partners Group to release IMs for Civica sale in mid-September
  • Exits
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
  • Investments
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • 01 September 2023
Redalpine expands leadership team amid CHF 1bn-plus fundraise
  • Venture
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • 31 August 2023
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • 31 August 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013